SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE L impact

Marvel Biosciences awards 50,001 deferred share units to independent directors

Marvel Biosciences Corp. (and its wholly owned subsidiary) announced the award of 50,001 deferred share units (DSUs) to its three independent directors.

MRVL

Calgary, Alberta--(. - September 1, 2026) - Marvel Biosciences Corp.

TSXV:MRVL and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 50,001 deferred share units ("DSUs") to Marvel's three independent directors, in li…